Ignite Creation Date:
2025-12-25 @ 2:20 AM
Ignite Modification Date:
2026-01-26 @ 4:14 AM
Study NCT ID:
NCT01625234
Status:
COMPLETED
Last Update Posted:
2021-10-06
First Post:
2012-06-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Sponsor:
Xcovery Holdings, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
X396-CLI-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None